NeoTherma Oncology

OverviewSuggest Edit

NeoTherma Oncology is a clinical-stage medical device company that specializes in cancer treatment. It develops VectRx, a thermal treatment (TTx) system designed for deep solid tumors. The company uses technology based on applying a non-invasive and nonionizing electromagnetic field to produce local fever-range temperatures in tumor tissue, intended to support the effectiveness of anticancer radiotherapy, chemotherapy, and immunotherapy.
TypePrivate
Founded2015
HQWichita, KS, US
Websiteneothermaoncology.com

Locations

NeoTherma Oncology is headquartered in
Wichita, United States

Location Map

Latest Updates

Employees (est.) (Nov 2021)9
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

NeoTherma Oncology Office Locations

NeoTherma Oncology has an office in Wichita
Show all (1)

NeoTherma Oncology Financials and Metrics

Summary Metrics

Founding Date

2015

NeoTherma Oncology total Funding

$6 m

NeoTherma Oncology latest funding size

$6 m

Time since last funding

3 years ago

NeoTherma Oncology investors

NeoTherma Oncology's latest funding round in August 2018 was reported to be $6 m. In total, NeoTherma Oncology has raised $6 m
Show all financial metrics

NeoTherma Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

NeoTherma Oncology Online and Social Media Presence

Embed Graph

NeoTherma Oncology Frequently Asked Questions

  • When was NeoTherma Oncology founded?

    NeoTherma Oncology was founded in 2015.

  • How many employees does NeoTherma Oncology have?

    NeoTherma Oncology has 9 employees.

  • Who are NeoTherma Oncology competitors?

    Competitors of NeoTherma Oncology include Vitanova Biomedical, SIVA Therapeutics and NovoCure.

  • Where are NeoTherma Oncology offices?

    NeoTherma Oncology has an office in Wichita.

  • How many offices does NeoTherma Oncology have?

    NeoTherma Oncology has 1 office.